Research programme: hepatitis C therapy - Immtech

Drug Profile

Research programme: hepatitis C therapy - Immtech

Alternative Names: HCV therapies - Immtech

Latest Information Update: 24 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immtech Pharmaceuticals
  • Class
  • Mechanism of Action DNA inhibitors; Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 24 Sep 2010 Preclinical development is ongoing in USA
  • 03 Jun 2008 Interim pharmacodynamics data from a preclinical trial in HCV assay released by Immtech
  • 27 Nov 2007 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top